跳转至内容
Merck
  • Effect of methylphenidate treatment during adolescence on norepinephrine transporter function in orbitofrontal cortex in a rat model of attention deficit hyperactivity disorder.

Effect of methylphenidate treatment during adolescence on norepinephrine transporter function in orbitofrontal cortex in a rat model of attention deficit hyperactivity disorder.

Journal of neuroscience methods (2015-02-15)
Sucharita S Somkuwar, Kathleen M Kantak, Linda P Dwoskin
摘要

Attention deficit hyperactivity disorder (ADHD) is associated with hypofunctional medial prefrontal cortex (mPFC) and orbitofrontal cortex (OFC). Methylphenidate (MPH) remediates ADHD, in part, by inhibiting the norepinephrine transporter (NET). MPH also reduces ADHD-like symptoms in spontaneously hypertensive rats (SHRs), a model of ADHD. However, effects of chronic MPH treatment on NET function in mPFC and OFC in SHR have not been reported. In the current study, long-term effects of repeated treatment with a therapeutically relevant oral dose of MPH during adolescence on NET function in subregions of mPFC (cingulate gyrus, prelimbic cortex and infralimbic cortex) and in the OFC of adult SHR, Wistar-Kyoto (WKY, inbred control) and Wistar (WIS, outbred control) rats were determined using in vivo voltammetry. Following local ejection of norepinephrine (NE), uptake rate was determined as peak amplitude (Amax)× first-order rate constant (k-1). In mPFC subregions, no strain or treatment effects were found in NE uptake rate. In OFC, NE uptake rate in vehicle-treated adult SHR was greater than in adult WKY and WIS administered vehicle. MPH treatment during adolescence normalized NE uptake rate in OFC in SHR. Thus, the current study implicates increased NET function in OFC as an underlying mechanism for reduced noradrenergic transmission in OFC, and consequently, the behavioral deficits associated with ADHD. MPH treatment during adolescence normalized NET function in OFC in adulthood, suggesting that the therapeutic action of MPH persists long after treatment cessation and may contribute to lasting reductions in deficits associated with ADHD.

材料
货号
品牌
产品描述

Sigma-Aldrich
氯化钠, for molecular biology, DNase, RNase, and protease, none detected, ≥99% (titration)
Sigma-Aldrich
L -抗坏血酸, powder, suitable for cell culture, γ-irradiated
Sigma-Aldrich
L -抗坏血酸, BioXtra, ≥99.0%, crystalline
Sigma-Aldrich
氯化钠 溶液, 5 M in H2O, BioReagent, for molecular biology, suitable for cell culture
Sigma-Aldrich
氯化钠 溶液, 0.9% in water, BioXtra, suitable for cell culture
Sigma-Aldrich
氯化钠, BioReagent, suitable for cell culture, suitable for insect cell culture, suitable for plant cell culture, ≥99%
Sigma-Aldrich
L -抗坏血酸, suitable for cell culture, suitable for plant cell culture, ≥98%
Sigma-Aldrich
高氯酸, 70%, 99.999% trace metals basis
SAFC
氯化钠 溶液, 5 M
Sigma-Aldrich
L -抗坏血酸, reagent grade, crystalline
Sigma-Aldrich
氯化钠, JIS special grade, ≥99.5%
Sigma-Aldrich
氯化钠 溶液, BioUltra, for molecular biology, ~5 M in H2O
Sigma-Aldrich
氯化钠, BioUltra, for molecular biology, ≥99.5% (AT)
Sigma-Aldrich
氯化钠, 99.999% trace metals basis
Sigma-Aldrich
尿烷, ≥99%
Sigma-Aldrich
L -抗坏血酸, reagent grade
Sigma-Aldrich
L -抗坏血酸, meets USP testing specifications
Sigma-Aldrich
氯化钠, BioXtra, ≥99.5% (AT)
Sigma-Aldrich
L -抗坏血酸, 99%
Sigma-Aldrich
氯化钠, SAJ first grade, ≥99.0%
Sigma-Aldrich
L -抗坏血酸, FCC, FG
Sigma-Aldrich
L -抗坏血酸, BioUltra, ≥99.5% (RT)
Sigma-Aldrich
氯化钠, meets analytical specification of Ph. Eur., BP, USP, 99.0-100.5%
Sigma-Aldrich
高氯酸, 0.1 M
Sigma-Aldrich
尿烷, ≥99.0% (GC)
Sigma-Aldrich
L -抗坏血酸, ACS reagent, ≥99%
Sigma-Aldrich
氯化钠, BioPerformance Certified, ≥99% (titration), suitable for insect cell culture, suitable for plant cell culture
Sigma-Aldrich
氯化钠 溶液, 5 M
Sigma-Aldrich
氯化钠, AnhydroBeads, −10 mesh, 99.999% trace metals basis
Sigma-Aldrich
氯化钠-35Cl, 99 atom % 35Cl